Pfizer has announced longer-term follow-up results from the Phase 3 CROWN trial, evaluating Lorlatinib, a lung cancer treatment in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After five years of median follow-up,
